000			03635nam a22003975i 4500
001			81466
003			ES-MaUEC
005			20230207040331.0
007			cr nn 008mamaa
008			150907s2015 gw | s |||| 0|eng d
020			_a9783319202730
024	7		_a10.1007/978-3-319-20273-0 _2doi
050		4	_aRC382 _b.T443 2015
245	1	4	_aThe Adenosinergic System : _bA Non-Dopaminergic Target in Parkinsonâ€{u3804}isease _cedited by Micaela Morelli, Nicola Simola, Jadwiga Wardas.
250			_a1st ed. 2015.
260			_aCham, Switzerland _bSpringer _c2015
300			_a1 recurso en línea (XII, 337 páginas) _b41 ilustraciones, 31 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCurrent Topics in Neurotoxicity _x2363-9563 _v10
505	0		_aAdenosine A2A receptors: localization and function -- Allosteric Mechanisms in the adenosine A2A-dopamine D2 receptor heteromer -- Adenosine A2A receptor antagonists in drug development -- Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease -- Role of adenosine A2A receptors in the control of neuroinflammation â€{u0CA5}levance for Parkinsonâ€{u3824}isease -- Purines in Parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection -- Adenosine A2A receptor antagonists as drugs for symptomatic control of Parkinsonâ€{u3824}isease in preclinical studies -- Dopamine/adenosine interactions related to tremor in animal models of Parkinsonism -- Adenosine A2A receptor antagonists in L-DOPA-induced motor fluctuations -- Adenosine A2A receptor-mediated control of non-motor functions in Parkinsonâ€{u3824}isease -- Imaging Studies with A2A Receptor Antagonists -- Caffeine and neuroprotection in Parkinson's disease -- The story of istradefylline â€{u0D28}e first approved A2A antagonist for the treatment of Parkinsonâ€{u3824}isease -- Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease -- Adenosinergic regulation of sleep-wake behavior in the basal ganglia.
520	3		_aAdenosine A2A receptor antagonists have shown great promise in the treatment of Parkinson's Disease and alleviation of symptoms.This bookÂ{u1924}resses various aspects of this class of drugs from their chemical development to their clinical use. Among the many insightful chapters contained in this book, there are three unique reviews that have not previously been published in any format: (1) a history of istradefylline, the first A2A antagonist approved for treatment of Parkinson's Disease, (2) an overview of neuroimaging studies in human health and disease, and (3) a study of urate as a possible biomarker and neuroprotectant.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
988			_aEBOOK, asignarmaterias, EBSPRINGER,
650		7	_aNeurociencias _0 _2embne _9158907
650	2	7	_aNeurociencias _0 _2embne _9158907
700	1		_aMorelli, Micaela _eeditor literario _993910 _0Local
700	1		_aSimola, Nicola _eeditor literario _993911 _0Local
700	1		_aWardas, Jadwiga _eeditor literario _993912 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-20273-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12900564 _b10-10-17 _c18-01-16
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h4
945			_aRC382 .T443 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11570180 _z06-04-17
999			_c81466 _d81466 _x1